FDA Waxman/Hatch Policy Change Afforded Full White House Honors
Executive Summary
The White House Waxman/Hatch reform proposal reflects the policy development approach of FDA Chief Counsel Daniel Troy - and the Administration-insider status of incoming Commissioner Mark McClellan
You may also be interested in...
FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said
FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said
Generic Drug Reform Outlook: Medicare Rx Bill May Be Best Vehicle
The best opportunity to push Waxman/Hatch reforms in the next Congress will likely be in the context of a Medicare prescription drug benefit bill